Saralasin

This classification denotes an antihypertensive agent with the molecular formula C42H65N13O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H2AFV2HE66, chemically known as angiotensin ii, 1-(n-methylglycine)-5-l-valine-8-l-alanine- but generally known as saralasin, which bears US NIH Compound Identifier 36736. European Medicines Agency schedules Saralasin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10447MIG. The term SARALASIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 28, No. 10 1974, List 14). SARALASIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule saralasin under HS 29371900 and SITC 54154. As of Q4 2014, SARALASIN remains the US FDA Preferred Term for this commodity. Saralasin bears US NLM identifiers UMLS ID C0036193 and NCI Concept Code C66527. SMILES: O=C(N1C(CCC1)C(=O)NC(C)C(=O)O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC)CCC/N=C(/N)N)C(C)C)Cc1ccc(O)cc1)C(C)C)Cc1[nH]cnc1.